Comparative Pharmacology
Head-to-head clinical analysis: KETOTIFEN FUMARATE versus TELDRIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: KETOTIFEN FUMARATE versus TELDRIN.
KETOTIFEN FUMARATE vs TELDRIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Antihistamine and mast cell stabilizer; inhibits release of histamine and other mediators from mast cells; also blocks histamine H1 receptors.
TELDRIN contains loratadine and pseudoephedrine. Loratadine is a long-acting tricyclic antihistamine with selective peripheral H1-receptor antagonism. Pseudoephedrine is a sympathomimetic amine that acts as a decongestant by stimulating alpha-adrenergic receptors in the respiratory tract mucosa, causing vasoconstriction.
1 mg orally twice daily; ophthalmic: 1 drop in each eye every 8-12 hours.
1-2 mg orally twice daily; maximum 4 mg/day.
None Documented
None Documented
Terminal half-life 12-24 hours (mean 18 hours); requires twice-daily dosing after initial titration.
Terminal half-life: 9-12 hours (range 8-14) in healthy adults; prolonged in renal impairment.
Renal (50-70% as conjugates, <2% unchanged), fecal (<10%), with enterohepatic circulation.
Renal: 55-60% unchanged; fecal: 35-40%; minor biliary elimination.
Category A/B
Category C
Antihistamine / Mast Cell Stabilizer
Antihistamine